Tests diclofenac added to a PD-1 inhibitor in metastatic melanoma

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma that has spread and cannot be removed by surgery. They must already be on a PD-1 inhibitor with stable disease as the best response.

Age

18 years or older

Sex

All sexes can join.

Disease stage

Melanoma that has spread and cannot be removed by surgery, confirmed by tissue examination. Best response to the current PD-1 therapy is stable disease (SD) by RECIST 1.1.

Earlier treatment

Must be on an approved anti-PD-1 therapy now. People with a BRAF-V600 mutation must have had targeted therapy.

Biomarker or test result

BRAF-V600 mutation is not required, but people who have it must have had targeted therapy.

Main reasons for not taking part

• Brain metastases with symptoms, or metastases in the membranes around the brain
• Uveal or mucosal melanoma
• History of heart failure (NYHA III-IV), heart attack or stroke
• History of stomach ulcer or bleeding in the digestive tract
• Known allergy to diclofenac

The registry criteria, word for word

What the trial wants to find out

To evaluate the efficacy of diclofenac added to an approved, ongoing PD-1 inhibitor therapy that achieved SD as best response in metastatic melanoma patients.